Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Interleukin Antagonists

Interleukin Antagonists Editorial Have We Found the Right One to Block? Are Cardiovascular Effects of Biologic Therapies Similar? Ayman Samman Tahhan, MD; Pratik B. Sandesara, MD; Arshed A. Quyyumi, MD here is strong experimental and clinical support for a recognized. However, randomized controlled trials with Tcausal role of immune dysregulation and inflammation in TNF-α antagonists were disappointing and associated with atherosclerosis and heart failure. Atherosclerotic lesions are increased risk in heart failure. Novel therapies targeted infiltrated by monocytes, macrophages, and T lymphocytes against specific cytokines in the inflammatory cascade, such (predominantly Th1). Cytokines, including interleukin-6 (IL- as IL-12, are currently under investigation for treatment 6) and tumor necrosis factor-α (TNF-α), are released by the of a variety of disorders. Ustekinumab is one of the several infiltrating inflammatory cells and stimulate adhesion mol- human monoclonal antibodies targeting the subunit (p40) of ecule expression. IL-6 can downregulate nitric oxide produc- IL-12 and IL-23 that was approved by the Food and Drug tion and further worsen endothelial dysfunction. Progression Administration in 2009 for treatment of psoriasis. Recent data of this inflammatory response is primarily regulated by spe- suggest that Ustekinumab may improve psoriasis by inhibit- cific patterns of cytokine expression. Interleukin 12 (IL-12) ing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Circulation: Cardiovascular Imaging Wolters Kluwer Health

Interleukin Antagonists

Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/interleukin-antagonists-mFkMNaa0ih

References (22)

Publisher
Wolters Kluwer Health
Copyright
© 2017 American Heart Association, Inc.
ISSN
1941-9651
eISSN
1942-0080
DOI
10.1161/CIRCIMAGING.117.006919
Publisher site
See Article on Publisher Site

Abstract

Editorial Have We Found the Right One to Block? Are Cardiovascular Effects of Biologic Therapies Similar? Ayman Samman Tahhan, MD; Pratik B. Sandesara, MD; Arshed A. Quyyumi, MD here is strong experimental and clinical support for a recognized. However, randomized controlled trials with Tcausal role of immune dysregulation and inflammation in TNF-α antagonists were disappointing and associated with atherosclerosis and heart failure. Atherosclerotic lesions are increased risk in heart failure. Novel therapies targeted infiltrated by monocytes, macrophages, and T lymphocytes against specific cytokines in the inflammatory cascade, such (predominantly Th1). Cytokines, including interleukin-6 (IL- as IL-12, are currently under investigation for treatment 6) and tumor necrosis factor-α (TNF-α), are released by the of a variety of disorders. Ustekinumab is one of the several infiltrating inflammatory cells and stimulate adhesion mol- human monoclonal antibodies targeting the subunit (p40) of ecule expression. IL-6 can downregulate nitric oxide produc- IL-12 and IL-23 that was approved by the Food and Drug tion and further worsen endothelial dysfunction. Progression Administration in 2009 for treatment of psoriasis. Recent data of this inflammatory response is primarily regulated by spe- suggest that Ustekinumab may improve psoriasis by inhibit- cific patterns of cytokine expression. Interleukin 12 (IL-12) ing

Journal

Circulation: Cardiovascular Imaging – Wolters Kluwer Health

Published: Sep 1, 2017

There are no references for this article.